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A B S T R A C T
Background
UNAIDS estimates that 34 million people are currently living with the human immunodeficiency virus (HIV) worldwide. Currently
recommended regimens for initiating HIV treatment consist of either a non-nucleoside reverse transcriptase inhibitor (NNRTI) or
ritonavir-boosted protease inhibitor (PI) combined with two nucleoside reverse transcriptase inhibitors (NRTIs). However, there may
be some patients for whom NNRTIs and PIs may not be appropriate. This is an update of the review published in the Cochrane Library
Issue 3, 2009.
Objectives
To evaluate the effects of any fixed-dose combination of three NRTIs (co-formulated abacavir-lamivudine-zidovudine) for initial
treatment of HIV infection.
Search methods
Between December 2010 and July 2011, we used standard Cochrane methods to search electronic databases and conference proceedings
with relevant search terms without limits to language or publication status.
Selection criteria
We selected randomised controlled trials (RCTs) with a minimum follow-up time of six months which compared co-formulated
abacavir-lamivudine-zidovudine with either PI-based or NNRTI-based therapy among antiretroviral-naive HIV-infected patients aged
at least 13 years.
Data collection and analysis
Three authors independently selected eligible studies, assessed risk of bias, and extracted data; resolving discrepancies by consensus. We
calculated the risk ratio (RR) or mean difference (MD), as appropriate, with its 95% confidence interval (CI) and conducted meta-
analysis using the random-effects method because of significant statistical heterogeneity (P<0.1).
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Main results
We identified 15 potentially eligible RCTs, four of which met our inclusion criteria. The four included RCTs were conducted in the
United States of America (USA); USA, Puerto Rico, Guatemala, Dominican Republic, and Panama; USA and Mexico; and Botswana,
respectively. The RCTs compared co-formulated abacavir-lamivudine-zidovudine to treatment based on efavirenz (NNRTI), nelfinavir
(PI), atazanavir (PI), and co-formulated lopinavir-ritonavir (PI), respectively. Overall, there was no significant difference in virological
suppression between co-formulated abacavir-lamivudine-zidovudine and NNRTI- or PI-based therapy (4 trials; 2247 participants: RR
0.73, 95% CI 0.39 to 1.36). However, the results showed significant heterogeneity (I2=79%); with co-formulated abacavir-lamivudine-
zidovudine inferior to NNRTI (1 trial, 1147 participants: RR 0.35, 95%CI 0.26 to 0.49) but with a trend towards co-formulated
abacavir-lamivudine-zidovudine being superior to PI (3 trials, 1110 participants: RR 1.07, 95%CI 1.00 to 1.16; I2=0%). We found no
significant differences between co-formulated abacavir-lamivudine-zidovudine and either PI or NNRTI on CD4+ cell counts (3 trials,
1687 participants: MD -0.01, 95%CI -0.11 to 0.09; I2=0%), severe adverse events (4 trials: RR 1.22, 95%CI 0.78 to 1.92; I2=62%)
and hypersensitivity reactions (4 trials: RR 4.04, 95% CI 0.41 to 40.02; I2=72%). Only two studies involving PIs reported data on
the lipid profile. One study found that the mean increase in total cholesterol from baseline to 96 weeks was significantly lower with
co-formulated abacavir-lamivudine-zidovudine than with nelfinavir, but there were no differences with triglyceride levels. The second
study found the fasting lipid profile to be comparable in both co-formulated abacavir-lamivudine-zidovudine and atazanavir arms at
48 weeks.
The significant heterogeneity of effects for most outcomes evaluated was largely due to differences in the control therapy used in the
included trials (i.e. NNRTIs or PIs). Using the GRADE approach, we rated the overall quality of the evidence on the relative effects of
co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection as moderate. The main reason for downgrading
the quality of the evidence was imprecision of the findings. The estimate of the treatment effect for each outcome has wide confidence
intervals, which extend from the fixed-dose NRTI combination regimen being appreciably better to the regimen being appreciably
worse than PI- or NNRTI-based regimens.
Authors’ conclusions
This review provides evidence that co-formulated abacavir-lamivudine-zidovudine remains a viable option for initiating antiretroviral
therapy, especially in HIV-infected patients with pre-existing hyperlipidaemia. The varied geographical locations of the included trials
augment the external validity of these findings. We are moderately confident in our estimate of the treatment effects of the triple NRTI
regimen as initial therapy for HIV infection. In the context of the GRADE approach, such moderate quality of evidence implies that
the true effects of the regimen are likely to be close to the estimate of effects found in this review; but there is a possibility that they could
be substantially different. Further research should be geared towards defining the subgroup of HIV patients for whom this regimen
will be most beneficial.
P L A I N L A N G U A G E S U M M A R Y
Co-formulated abacavir-lamivudine-zidovudine for treating HIV infection and AIDS
The primary objective of this review was to evaluate the antiviral efficacy of co-formulated abacavir-lamivudine-zidovudine for initial
treatment of HIV infection. The secondary objectives were to evaluate the safety and tolerability of the triple drug combination. We
identified 15 potentially eligible studies, four of which met our inclusion criteria. Our findings indicate that co-formulated abacavir-
lamivudine-zidovudine remains a viable option for initiating antiretroviral therapy, especially in HIV-infected patients with pre-existing
hyperlipidaemia and those who do not tolerate ritonavir.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Co-formulated abacavir-lamivudine-zidovudine compared to NNRTIs or PIs for initial treatment of HIV infection and AIDS
Patient or population: Antiretroviral-naive HIV infected patients
Settings: Any country setting (i.e. low-, middle-, or high-income)
Intervention: Co-formulated abacavir-lamivudine-zidovudine
Comparison: Non-nucleoside reverse transcriptase inhibitor (NNRTI)- or protease inhibitor (PI)-based therapy




Quality of the evidence
(GRADE)
Assumed risk Corresponding risk
NNRTIs or PIs Co-formulated abacavir-
lamivudine-zidovudine
Virologic failure
2 successive HIV-1 RNA >=
200copies/ml at 16+ weeks
after randomisation
Follow-up: mean 48 weeks









Viral load <50 copies/ml
Follow-up: mean 48 weeks









Follow-up: mean 48 weeks
The mean CD4 cell count
ranged across control groups
from
415-634 cells per cubic mil-
limetres
The mean CD4 cell count in
the intervention groups was
0.01 lower
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.





















































































































B A C K G R O U N D
The human immunodeficiency virus (HIV) pandemic poses one
of the greatest challenges to global public health. In 2011, an esti-
mated 34 million people were living with HIV and 1.7 million died
of the acquired immunodeficiency syndrome (AIDS) (UNAIDS
2012). Prevention is commonly advocated to curb the spread of
HIV infection, and although preventive methods have consider-
ably slowed the spread of HIV in most parts of the world, people
who are already infected need care and treatment.
The goal of antiretroviral therapy is to achieve prolonged sup-
pression of HIV replication. The ideal antiretroviral drugs should
be effective in suppressing viral replication, affordable, available
in simplified regimens, well tolerated, and have no dietary in-
teractions. The use of monotherapy and dual therapy has often
led to mutations and long-term resistance (Eron 1995; Pialoux
1998; Rutherford 2003), necessitating the development of combi-
nation therapy with three drugs taken separately (Carpenter 2000;
Hammer 2008). In well-resourced countries (Ledergerber 1999)
and, recently, Brazil (Hacker 2004; Teixeira 2004), antiretrovi-
ral therapy has contributed substantially towards delaying HIV
progression to AIDS and death. However, these combinations are
complex and difficult to take due to high pill burden, stringent
intake schedules, and food and fluid restrictions They may also be
associated with drug-drug interactions and numerous side effects,
including various lipid abnormalities (Mehta 1997; Gifford 2000).
This complexity also makes antiretroviral therapy less accessible to
patients in most resource-constrained regions of the world, which
currently are hardest hit by the pandemic, such as sub-Saharan
Africa. This area is inhabited by approximately 10% of the world’s
population but is home to 60% of all people currently living with
HIV (UNAIDS 2012).
Concern over toxicity, adherence, and drug-drug interactions has
led to the development of simpler antiretroviral regimens, includ-
ing co-formulated abacavir-lamivudine-zidovudine (Anon 2000;
Saez-Llorens 2001). Three NRTIs simplify PI-based therapy by
easing dosing regimens (only one tablet twice daily) and avoiding
lipid abnormalities (Seaton 2003). Although treatment simplifica-
tion could help patients maintain adherence, continued virologic
suppression must be ensured. Therefore, clarification of the role of
this simplified antiretroviral therapy on prolonged suppression of
HIV replication is of considerable importance. Because all three
antiretroviral drugs are of the same class, the use of co-formulated
abacavir-lamivudine-zidovudine (if proven to be effective) poten-
tially preserves NNRTIs and PIs for later use, thereby avoiding
resistance to all classes of antiretroviral agents at the same time,
and allows for effective second-line treatment regimens (Staszewski
2001). There are concerns, however, about hypersensitivity re-
actions to abacavir (Staszewski 1998). Cross resistance between
drugs of the same class should also be considered. Also, entecavir
used for hepatitis B virus (HBV) treatment, may select for M184V
mutation which confers resistance to lamivudine in individuals
co-infected with HIV and HBV (McMahon 2007).
The aim of this review was to combine all high-quality RCTs com-
paring co-formulated abacavir-lamivudine-zidovudine with PI- or
NNRTI-based therapy to assess the antiviral potency and toler-
ability of the simplified triple nucleoside combination in initial
therapy for HIV.
O B J E C T I V E S
The primary objective of this review was to evaluate the antiviral
efficacy of co-formulated zidovudine-lamivudine-abacavir for ini-
tial treatment of HIV infection. The secondary objectives were to
evaluate the safety and tolerability of the triple nucleoside combi-
nation.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Only RCTs with a minimum follow-up time of six months were
included. Six months of treatment was considered enough time
to detect significant differences in the suppression of viral activity
after initiation of therapy.
Types of participants
HIV-infected, antiretroviral-naive patients aged at least 13 years.
We chose only studies that focused on adolescents and adults.
Types of interventions
Treatment of HIV infection with co-formulated abacavir-lamivu-
dine-zidovudine as initial therapy compared with treatment based
on PIs or NNRTIs
Types of outcome measures
The primary outcome measure was suppression of viral activity, as
defined by the authors.
The secondary outcome measures included:
1- CD4 cell count
2- Severe adverse events
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Search methods for identification of studies
See: HIV/AIDS Collaborative Review Group search strategy.
Between February 2008 and May 2009, we searched PubMed,
EMBASE, Cochrane Database of Systematic Reviews, and the
York Database of Abstracts of Reviews of Effectiveness (DARE)
for previous reviews and meta-analyses of antiretroviral therapy for
treatment of HIV that included co-formulated abacavir-lamivu-
dine-zidovudine; and searched the references of these reviews for
reports of eligible trials. We then carried out an exhaustive search
of the Cochrane Central Register of Controlled Trials (CEN-
TRAL), PubMed, EMBASE, NLM GATEWAY, and AIDSearch,
for randomised controlled trials of co-formulated abacavir-lamivu-
dine-zidovudine for initial treatment of HIV, using standardised
methodological filters (Higgins 2011) where appropriate. We also
searched reference lists of identified articles.There were no time or
language restrictions to our search.
We updated the search in December 2010 by searching EM-
BASE, ISI Web of Science, PsycINFO, ClinicalTrials.gov, and
the WHO International Clinical Trials Registry Platform (http:/
/www.who.int/ictrp/search/en/). In addition, in July 2011, we fi-
nalised the update by searching CENTRAL, and PubMed.
See Appendix 1 for all search strategies.
Data collection and analysis
See: Cochrane HIV/AIDS Group methods used in reviews.
Selection of studies
The Trials Search Coordinator of the Cochrane HIV/AIDS
Group (http://www.igh.org/Cochrane/) conducted the electronic
database searches. For the original version of the review and this
update, three authors (MS, EJK, and CSW) independently con-
ducted the selection of potentially relevant studies by scanning
the titles and abstracts of all material downloaded from the elec-
tronic searches. Irrelevant reports were discarded and the full ar-
ticles were obtained for all potentially relevant or uncertain re-
ports. From this pool of potentially eligible studies, we selected
studies for inclusion in the review if they were RCTs (study de-
sign) comparing any fixed-dose combination of abacavir, lamivu-
dine and zidovudine (NRTI) with PI- or NNRTI-based antiretro-
viral therapy (intervention) in antiretroviral-naive, HIV-infected
adults (participants). Disagreements between the review authors
were resolved by discussion and consensus. When no consensus
could be reached, SMA and JS arbitrated.
Data extraction and management
The three authors (MS, EJK, and CSW) extracted data inde-
pendently using pre-established data collection forms. We ex-
tracted information from included studies on study details (i.e.
how the allocation sequence was generated, method used to con-
ceal treatment allocation, blinding of those receiving and provid-
ing care and those assessing outcomes, losses to follow-up and
how they were handled), participant characteristics (i.e. setting,
number of patients randomised, baseline HIV-1 RNA and CD4
cell levels), interventions (i.e. treatment and control, length of
treatment), and outcomes (virological failure/suppression, CD4+
cell count, cholesterol level, clinical lipodystrophy manifestations,
other side effects). Disagreements between the review authors were
resolved by discussion and consensus. When no consensus could
be reached, SMA and JS arbitrated.
Assessment of risk of bias in included studies
We assessed risk of bias as outlined in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). Three
review authors (MS, EJK, and CSW) independently assessed the
risk of bias in each included study by addressing seven specific do-
mains, namely, random sequence generation, allocation conceal-
ment, blinding of participants and personnel, blinding of outcome
assessment, incomplete outcome data, selective outcome report-
ing, and ‘other issues’. For each included trial, the authors inde-
pendently described what the study authors reported that they did
for each domain and then made a decision relating to the risk of
bias for that domain by assigning a judgement of ’Low risk’ of bias,
’High risk’ of bias, or ’Unclear risk’ of bias. The review authors
compared the results of their independent assessments of risk of
bias and resolved any discrepancies by discussion and consensus.
When no consensus could be reached, SMA and JS arbitrated.
For study selection, data extraction, and risk of bias assessment we
were not blinded to the names of the trial authors, their institu-
tions, nor the journals of publication.
Data synthesis
We undertook meta-analysis using RevMan 5. We analysed all
participants in the groups to which they were randomised, irre-
spective of whether they received the allocated intervention, and
assessed heterogeneity between study results using the chi-square
test of homogeneity, with significance defined at the 10% level
(www.cochrane-handbook.org). We expressed each trial result as
a risk ratio (RR) for dichotomous data and mean difference (MD)
for continuous data, with 95% confidence intervals (CIs), and
combined the results using the random-effects method because
of significant heterogeneity. We also used the I2 statistic to de-
scribe the percentage of between-study variability in effect es-
timates, which is attributable to true heterogeneity rather than
chance (Higgins 2011).
We used the GRADE method to rate the quality of evidence on the
effectiveness of the triple NRTI regimen (Guyatt 2008; Balshem
2011), and have presented these ratings in Summary of findings
for the main comparison. The GRADE approach results in an
assessment of the quality of a body of evidence as high, moderate,
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low, or very low. High quality evidence implies that “further re-
search is very unlikely to change our confidence in the estimate of
effect”. Moderate quality evidence means “further research is likely
to have an important impact on our confidence in the estimate
of effect and may change the estimate”. Evidence is considered of
low quality if “further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely to
change the estimate”, and very low quality if “we have very little
confidence in the effect estimate”. In this review we considered
five factors when grading the quality of evidence on the relative
effects of fixed-dose NRTI regimen for initiating HIV treatment;
namely, risk of bias in included RCTs, unexplained heterogeneity
of effects, indirectness of the evidence, imprecision of the find-
ings, and possibility of publication bias. Regarding risk of bias,
we were most concerned with lack of allocation concealment, lack
of blinding of outcome assessment, and a large loss to follow-up.
Heterogeneity of effects across studies for which there were no
compelling explanations would also have reduced our confidence
in the evidence. Indirectness refers to differences between the pop-
ulation, intervention, comparison group and outcome of interest
to us, and those reported by the included RCTs. For imprecision,
if we found that studies included relatively few participants and
few events and thus had estimates of effects with wide confidence
intervals, we rated down the quality of the evidence. Finally, we
would also have rated down the quality of evidence if there was a
high likelihood of publication bias (Balshem 2011).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies.
After scanning the titles and abstracts of all material obtained from
the searches conducted from February 2008 to July 2011 (Table 1;
Table 2; Table 3; Table 4; Table 5; Table 6; Table 7; Table 8; Table
9; Table 10; Table 11), and discarding clearly irrelevant reports,
we obtained 15 potentially eligible studies. We reviewed the full-
text articles of the 15 randomised controlled trials (Gulick 2004;
Kumar 2006; Kumar 2009; Shapiro 2010; Ait-Khaled 2002; Cahn
2004; d’Ettorre 2009; Feinberg 2003; Matheron 2003; Munderi
2010; Ndembi 2010; Shao 2009; Sprenger 2010; Staszewski 2001;
Vibhagool 2004) and four met our inclusion criteria (Gulick 2004;
Kumar 2006; Kumar 2009; Shapiro 2010).
The Gulick 2004 trial recruited 1147 participants from 33 units
of The AIDs Clinical Trials Group (ACTG) in the United States
of America (USA); the Kumar 2006 trial recruited 261 partici-
pants from 34 sites in the USA, Puerto Rico, Guatemala, Do-
minican Republic, and Panama; the Kumar 2009 study recruited
279 participants from 46 sites in the USA and Mexico; and the
Shapiro 2010 trial recruited 560 women in both urban and ru-
ral areas in Botswana. The four trials only included participants
who were antiretroviral-naive. The Gulick 2004 and Kumar 2009
trials recruited predominantly male participants (81% and 79%,
respectively), while only 50% of participants in the Kumar 2006
trial were men. Finally, all participants in the Shapiro 2010 trial
were women.
Participants in the Gulick 2004 trial had mean age 38 years (SD
9 years), were 40% white, 36% African American, and 21% His-
panic and had mean HIV-1 RNA level of 4.85 log10 copies/mL
(SD 0.70) and mean CD4+ cell count of 234 cells/mm3 (SD 187).
Participants in the Kumar 2006 trial had median age 34 years
(range 18-60 years), were 21% white, 40% African American, and
37% Hispanic, and had median HIV-1 RNA level of 4.44 log10
copies/mL (range 2.23 to 5.77) and median CD4 cell count of 339
cells/mm3 (range 19 to 1269). Participants in the Kumar 2009
study had median age 37 years (range 18 to 68 years), HIV-1 RNA
levels between 2.3 and 5.6 log10 copies/mL, and CD4+ cell counts
from 103 to 889 cells/mm3. Participants in the Shapiro 2010 trial
were pregnant women, aged 18 years or older, were presumably
all black Africans, and had median HIV-1 RNA levels of 13,300
copies/mL in the NRTI arm and 9,100 in the PI arm, and a CD4+
cell count of at least 200 cells/mm3 (median 393 cells/mm3 in the
NRTI arm and 403 cells/mm3 in the PI arm).
The participants in the Gulick 2004 trial were randomised to either
zidovudine (ZDV)-lamivudine(3TC)-abacavir (ABC) [Trizivir®],
or ZDV-3TC [Combivir®] + efavirenz [a NNRTI] or Trizivir® +
efavirenz. Participants took a total of seven pills per day, including
placebo tablets, divided into two doses. In the Kumar 2006 trial,
participants were assigned to either Trizivir® twice daily, or Com-
bivir® + nelfinavir [a PI] 1250 mg twice daily, or stavudine [d4T]
40 mg + 3TC 150 mg + nelfinavir 1250 mg twice daily. In Kumar
2009, participants were randomised to receive either Trizivir® or
atazanavir plus lamivudine and zidovudine. In Shapiro 2010, par-
ticipants were randomised to receive Trizivir® twice daily in the
NRTI arm, or 400 mg of lopinavir and 100 mg of ritonavir [co-
formulated as Kaletra®] twice daily in the PI arm. The Shaipro
2010 trial also had a third group of participants (observational
arm) who received Combivir® twice daily. This observational arm
was not included in our analysis.
Risk of bias in included studies
Our judgements about the risk of bias in each included study are
summarised in Figure 1 and Figure 2.
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Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Generation of allocation sequence
Three trials did not provide an adequate description of the meth-
ods used for generating the allocation sequence, but all were de-
scribed as randomised [Gulick 2004; Kumar 2006; Kumar 2009].
However, the equal allocation of participants suggests that a com-
puter-generated block randomisation process was used. In the
Shapiro 2010 trial, participants were randomly assigned to treat-
ment groups based upon computer-generated lists (Shapiro 2010).
Allo cation concealment
The Gulick 2004, Kumar 2009, and Shapiro 2010 trials used
central randomisation, suggesting that allocation concealment in
all three trials was adequate. The Kumar 2006 trial did not provide
sufficient detail to describe the allocation concealment process.
Blinding
In the Gulick 2004 trial, participants, providers, and outcome
assessors were all blinded. In the Kumar 2006 and Kumar 2009
trials, the participants and providers were not blinded, but it was
not clear if the outcome assessors were blinded. In the Shapiro
2010 trial, no details were given about blinding of participants,
providers, or outcome assessors.
Loss to follow-up
When the triple-nucleoside arm was stopped in the Gulick 2004
trial after a median of 32 weeks, 83 participants (7%) had dis-
continued the study for various reasons, including withdrawal of
consent (2%) and loss to follow-up (2%). In the Kumar 2006 trial,
loss to follow-up at 96 weeks was 26.4% for Trizivir® , 24.2% for
COM/NFV, and 14.5% for d4T/3TC/NFV groups. In the Ku-
mar 2009 trial, 9% and 10% of the participants were lost to fol-
low-up in the Trizivir® and ATV + 3TC/ZDV arms, respectively.
In the Shapiro 2010 trial 15(5.2%) women in the Trizivir® and
13(5.1%) in Kaletra® arms left the study for reasons that are not
stated.
Effects of interventions
See: Summary of findings for the main comparison
Co-formulated abacavir-lamivudine-zidovudine compared to
NNRTIs or PIs for initial treatment of HIV infection
There was significant heterogeneity between the included trials
in the incidence of virological failure (3 trials, 1687 participants,
heterogeneity P=0.009, I2=79%; Analysis 1.1). The Kumar studies
(Kumar 2006; Kumar 2009) did not find a significant difference in
the incidence of virological failure between participants on NRTIs
and those on a PI (i.e. nelfinavir or atazanavir) (two trials, 540
participants: RR 0.82, 95% CI 0.50 to 1.36; heterogeneity P=
0.21, I2=35%). Gulick and colleagues found that participants on
NRTIs had a significantly higher incidence of virological failure
than did those on the NNRTI efavirenz (1 trial, 1147 participants:
RR 1.93, 95% CI 1.46 to 2.55). Overall, there was no significant
difference between the participants on NRTIs and those on either
PI-based or NNRTI-based therapy (RR 1.14, 95% CI 0.56 to
2.32).
Whatever the definition of virological suppression considered,
there was significant heterogeneity between the four studies (het-
erogeneity P<0.00001, I2=93% for viral load<50copies/ml; het-
erogeneity P=0.0002, I2=85% for viral load <400 copies/mL) with
Kumar 2006, Kumar 2009 and Shapiro 2010 finding no signif-
icant differences between comparison groups and Gulick 2004
finding NRTIs to be inferior to efavirenz. For viral load of <50
copies/mL, the risk ratios were 1.15 (0.83 to 1.59) in the Kumar
2006 trial, 1.03 (0.85 to 1.25) in the Kumar 2009 trial, 0.73 (0.67
to 0.80) in the Gulick 2004 trial, 1.08 (0.99 to 1.17) in the Shapiro
2010 trial, and 0.97 (0.75 to 1.25) overall (Analysis 1.3). For viral
load of <400 copies/mL, the risk ratios were 1.10 (0.65 to 1.84)
in the Kumar 2006 trial, 0.96 (0.58 to 1.58) in the Kumar 2009
trial, 0.35 (0..26 to 0.49) in the Gulick 2004 trial, and 0.73 (0.39
to 1.36) overall (Analysis 1.2).
We found no significant differences between NRTIs and either
PIs or NNRTIs on CD4+ cell counts (3 trials, 1687 participants:
mean difference -0.01, 95% CI -0.11 to 0.09, I2=0%: Analysis
1.4), the incidence of severe adverse events (4 trials; 2247 partici-
pants: RR 1.22, 95% CI 0.78 to 1.92, I2=62%; Analysis 1.5) and
hypersensitivity reactions (RR 4.04, 95% CI 0.41 to 40.02, I2=
72%; Analysis 1.6). The Shapiro trial did not encounter a hyper-
sensitivity reaction in any treatment group.
Gulick 2004 and Shapiro 2010 did not report on lipid levels. At
week 96, Kumar 2006 found the least squares means increase in
total cholesterol from baseline was significantly lower with NR-
TIs than with nelfinavir. Kumar 2006 also found that mean total
cholesterol remained below 200mg/dL only in the NRTI group,
and the proportion of patients with total cholesterol levels more
than 200mg/dL after 96 weeks of treatment was significantly lower
in the NRTI group. At 96 weeks, Kumar 2006 found no significant
differences between the comparison groups in least squares means
triglyceride levels and least squares means change from baseline
in triglyceride levels. At 48 weeks, Kumar 2009 found the fasting
lipids to be comparable in both the NRTI and atazanavir arms.
Using the GRADE approach (Balshem 2011), we rated the quality
of the evidence on the relative effects of co-formulated abacavir-
lamivudine-zidovudine for initial treatment of HIV infection as
moderate outcome evaluated (Summary of findings for the main
comparison).
D I S C U S S I O N
The large Gulick 2004 trial found the co-formulated abacavir-
lamivudine-zidovudine regimen to be virologically inferior to a
regimen containing efavirenz and two or three nucleoside ana-
logues after 32 weeks; Kumar 2006 and Kumar 2009 found the
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triple nucleoside fixed-dose combination to be equivalent to nel-
finavir- and atazanavir-based regimens in maintaining virological
suppression over 96 weeks and 48 weeks, respectively; but Shapiro
2010 found viral suppression to be relatively superior in the co-
formulated abacavir-lamivudine-zidovudine arm compared to the
co-formulated lopinavir-ritonavir arm after six months of therapy.
The significant heterogeneity of effects was largely due to differ-
ences in the control therapy used in the included trials (i.e. NNR-
TIs or PIs). Pooling the four trials, we did not find significant
differences in virological suppression between initiating treatment
with the triple nucleoside fixed-dose combination (NRTI) and
therapy based on efavirenz (NNRTI), lopinavir-ritonavir (PI), nel-
finavir (PI), or atazanavir (PI). In addition, the triple nucleoside
fixed-dose combination regimen was well tolerated and had no
deleterious effects on the lipid profile. Using the GRADE approach
(Balshem 2011), we rated the overall quality of the evidence on
the relative effects of the fixed-dose NRTI regimen for initiating
HIV treatment as moderate. The main reason for downgrading
the quality of the evidence was imprecision of the findings. The
estimate of the treatment effect for each outcome has wide con-
fidence intervals, which extend from the fixed-dose NRTI com-
bination regimen being appreciably better to the regimen being
appreciably worse than PI- or NNRTI-based regimens (Summary
of findings for the main comparison).
The Shapiro 2010 trial examined the use of Trizivir® (NRTI)
or Kaletra® (PI) as first-line therapy in HIV-infected pregnant
women. Eventhough the rate of viral suppression after six months
of follow-up (up till postpartum period) did not show any differ-
ence between the interventions, there was a significant increase in
viral suppression to below 50 copies/ml with Trizivir® compared
to Keletra® at delivery (81% and 69%, respectively). This differ-
ence was not observed when the viral set point was raised to 400
copies/ml (Shapiro 2010).
The Kumar 2006 study compared NRTI with a PI (nelfinavir)
which is no longer a component of initial recommended regimen.
The comparator nelfinavir has been shown to be inferior to current
PI regimens both in tolerability and virological suppression and
is no longer a preferred treatment option (Moore 2006). There
is considerable heterogeneity amongst PIs as far as tolerability is
concerned, with newer members of the class, such as atazanavir,
very suitable for individuals with hyperlipidaemia (Kumar 2009).
Ritonavir-boosted PIs are now routinely used to initiate therapy
(Ananworanich 2008; Hammer 2008; Potard 2007). Ritonavir
was not included in any of the comparator arms of either the Ku-
mar or Gulick studies but was included in the Shapiro trial. How-
ever, ritonavir may not be appropriate for some HIV-infected pa-
tients, such as those with pre-existing hyperlipidaemia, metabolic
syndrome, underlying severe depression, and intolerance of riton-
avir. For the latter, it is important to have a treatment regimen that
is both efficacious and safe (Kumar 2009).
Treatment of antiretroviral-naive HIV-infected patients requires
regimens that have the potential to be used for a long period with-
out the fear of mutations often associated with failing regimens.
Treatment with co-formulated abacavir-lamivudine-zidovudine
offers the opportunity for patients to switch over to other antiretro-
viral classes in case of treatment failure. Patients failing on co-for-
mulated abacavir-lamivudine-zidovudine are unlikely to be asso-
ciated with emergence of multi-NRTI resistance (Shaefer 2004).
However, components of the fixed-dose combination regimen
have been associated with certain side effects (Shaefer 2004). Zi-
dovudine may cause anaemia in some patients, lamivudine is asso-
ciated with gastrointestinal adverse events, while abacavir is com-
monly associated with hypersensitivity reactions. Recent studies
have shown that abacavir is associated with fatal hypersensitivity
reactions in patients with a rare human leukocyte antigen (HLA)
allele, HLA-B*5701 (Mallal 2008; Hughes 2008; Saag 2008). This
suggests the need for genetic screening in individuals receiving
abacavir-based therapy to reduce the risk of hypersensitivity reac-
tions associated with the drug, which are often characterized by
two or more clinical signs or symptoms that can include fever,
rash, gastrointestinal symptoms, respiratory symptoms, and con-
stitutional symptoms. Shapiro and colleagues did not observe any
abacavir-related hypersensitivity reactions in their trial conducted
in Botswana as none of their participants tested positive for HLA-
B*5701 (Shapiro 2010).
Our findings indicate that the triple nucleoside fixed-dose combi-
nation remains a viable option for initiating anti-retroviral ther-
apy, especially in HIV-infected patients with pre-existing hyper-
lipidaemia; possibly preventing exacerbation of the condition and
obviating the need for antihyperlipidaemic agents and their in-
cumbent drug interactions. Like any other antiretroviral therapy,
constant monitoring of patients receiving this combination drug
is advised to detect any resistance or side effects that may be at-
tributed to abacavir, zidovudine, or lamivudine.
Publication and language biases are potential threats to all system-
atic reviews. We did not restrict our search to any language or pub-
lication status (published or unpublished). We are therefore con-
fident that we have identified all existing randomised controlled
trials relevant to our question but cannot rule out the possibility
that there are additional trials that are unpublished or published
in sources not accessible to our search.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
We found that co-formulated abacavir-lamivudine-zidovudine re-
mains a viable option for initiating anti-retroviral therapy, espe-
cially in HIV-infected patients with pre-existing hyperlipidaemia
and those who do not tolerate ritonavir. The varied geographi-
cal locations of the included trials augment the external validity
of our findings. We are moderately confident in our estimate of
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the treatment effects of the triple NRTI regimen as initial therapy
for HIV infection. In the context of the GRADE approach, such
moderate quality of evidence implies that the true effects of the
regimen are likely to be close to the estimate of effects found in
this review.
Implications for research
There is a need for antiretroviral treatment programmes to have
robust monitoring systems capable of identifying patients most
likely to develop severe adverse events, viral resistance, and muta-
tions. Further research on co-formulated abacavir-lamivudine-zi-
dovudine should be geared towards defining the subgroup of HIV
patients for whom this regimen will be most beneficial.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Gulick 2004
Methods Sequence generation: Patients were randomly assigned with equal opportunity to the
treatment arms. Treatment allocation was stratified by screening HIV-1 RNA levels
(<100,000 copies/ml or >=100,000 copies/mL)
Allocation concealment: Adequate (central remote randomisation)
Blinding: Participants, providers, and assessors all blinded.
Loss-to-follow-up: When the triple nucleoside arm was stopped, after a median of 32
weeks, 83 participants (7%) had discontinued the study for various reasons including
withdrawal of consent (n=21) and loss to follow-up (n=21).
Analysis: performed on an intention-to-treat basis and included all follow-up data
Participants Antiretroviral-naive HIV-1-infected adults recruited from 33 units of The AIDs Clinical
Trials Group (ACTG) in the US.
Exclusion criteria:
Immunomodulator investigational therapy or vaccines within previous 30 days, weight
less than 40kg, pregnancy, or lactation.
N=1147
Male 81%, mean age 38 (SD 9) years, whites 40%, blacks 36%, Hispanics 21%, mean
HIV-1 RNA level 4.85 log(10) copies/mL [SD 0.70), mean CD4 cell count = 234 cells/
mm3 (SD187). No significant levels between treatment arms.
Interventions Eligible subjects were randomly allocated to one of three regimens given orally at standard
doses and intervals:
Regimen A: zidovudine (ZDV)-lamivudine(3TC)-
abacavir (ABC) [Trizivir].
Regimen B: ZDV-3TC [Combivir] + efavirenz
Regimen C: ZDV-3TC-ABC + efavirenz.
Participants took a total of seven pills per day (including placebos), divided into two
doses.
In the event of treatment-limiting toxic effects of study drugs, the identity of the impli-
cated drug was allowed to
be revealed and substitution of another drug in the same class was permitted. Stavudine
could be substituted for ZDV, didanosine could be substituted for ABC, and nevirapine
could be substituted for efavirenz.
Outcomes 1. Virologic failure i.e. two successive HIV-1 RNA values of 200 or more copies/ml at
least 16 weeks after randomisation.
2. HIV-1 RNA level of less than 200 copies/ml and with a level below 50 copies/ml.
3. Change in CD4 cell count from base line
4. Adverse events
Notes The study was reviewed annually for safety and
efficacy by the data and safety monitoring board.
The second annual review showed differences between the triple-nucleoside regimen and
each of the efavirenz-containing regimens that met prespecified stopping guidelines, and
the DSMB recommended stopping the triple-nucleoside portion of the study, continuing
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Gulick 2004 (Continued)
double-blind follow-up of the other two groups, and analysing and presenting the results
with the data for the triple-nucleoside group compared with the pooled data from the
efavirenz groups. At the time of stopping the triple-nucleoside arm, the median duration
of follow-up was 32 weeks
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomly assigned with equal
opportunity to the treatment arms. Treat-
ment allocation was stratified by screening
HIV-1 RNA levels. Such an elaborate ran-
domisation sequence is likely to have been
computer-generated
Allocation concealment (selection bias) Low risk Central remote randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Participants and providers blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors all blinded.
Incomplete outcome data (attrition bias)
All outcomes
Low risk When the triple-nucleoside arm was
stopped in the Gulick 2004 trial after a me-
dian of 32 weeks, 83 participants (7%) had
discontinued the study for various reasons,
including withdrawal of consent (2%) and
loss to follow-up (2%)
Selective reporting (reporting bias) Low risk No
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Kumar 2006
Methods Sequence generation: Patients were “randomized 1:1:1” suggesting block randomisation,
but no detail of method of generating the randomisation sequence was given.
Allocation concealment: Not described.




26.4%(23/87) for Trizivir, 24.2% (22/91) in COM/NFV, and 14.5%(12/83) in d4T/
3TC/NFV groups.
Analysis: performed on an intention-to-treat basis.
Participants Partcipants recruited from 34 outpatient sites in USA, Puerto Rico, Guatemala, Do-
minican Republic & Panama.
Inclusion criteria:
Documented HIV infection; naive or limited experience with antiretroviral therapy;
age >= 18 years; CD4+ count > 50 cells/microL; 1000 copies/ml < HIV-1 RNA <
200,000 copies/ml. Exclusion criteria: pregnancy, lactation, , no antihyperlipidaemic or
antidiabetic medications.
N=261
Male 50%, median age 34 (range 18-60) years , Whites 20.9%, Blacks 39.8%, Hispanics
37.0%, median HIV-1 RNA level 4.44 log(10) copies/ml [range2.23-5.77), median
CD4 cell count = 339 cells/mm3 (range19-1269),
median total cholesterol 163mg/dl (92-267), median triglycerides 107 mg/dl (range38-
597)
No significant levels between treatment arms.
Interventions Patients meeting entry criteria were randomised 1:1:1 to:
Regimen A: Trizivir twice daily.
Regimen B: Combivir + nelfinavir 1250 twice daily.
Regimen C: Stavudine 40 mg + 3TC 150 mg + nelfinavir 1250 mg twice daily.
At enrolment participants were stratified into two groups based on their screening
plasma HIV-1 RNA level: <1000-100,000 copies/mL or
>100,000-200,000 copies/mL.
Outcomes 1. Change from baseline in LDL cholesterol.
2. Virologic failure i.e. two successive HIV-1 RNA values of 200 or more copies/ml at
least 16 weeks after randomisation.
2. HIV-1 RNA level of less than 200 copies/ml and with a level below 50 copies/ml.




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were “randomized 1:1:1” suggest-
ing block randomisation, and presumable
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computer-generated
Allocation concealment (selection bias) Unclear risk Not described.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and providers not blind
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow-up: 26.4% for Trizivir, 24.
2% in COM/NFV, and 14.5% in d4T/
3TC/NFV groups
Selective reporting (reporting bias) Low risk No
Kumar 2009
Methods Sequence generation: Patients were “randomized 1:1:1” suggesting block randomisation,
but no detail of method of generating the randomisation sequence was given
Allocation concealment: Adequate (central randomisation).
Blinding: No blinding
Loss to follow-up: 9% (12/138) in the ABC/3TC/ZDV and 10% (14/140) in the ATV
+ 3TC/ZDV groups
Analysis: Performed on an intent-to-treat exposed basis
Participants 279 subjects recruited between May 2004 and March 2005 from 46 sites in USA and
Mexico
Inclusion Criteria: HIV-1 infection, 18 years or older, ART-naive, and plasma HIV-1
RNA >=5000 but <200,000c/ML and CD4+ cell count >= 100 cells/mm3.
Exclusion criteria: Patients were excluded if they had medical conditions or required
medications that could compromise their safety or interfere with drug absorption, if they
had protocol-specific abnormal laboratory values
N=279
79% male and racially diverse (>50% non-white race or ethnicity), 82% had HIV-1
RNA <100,000c/mL at baseline
Interventions Patients meeting inclusion criteria were randomized 1:1 to receive ABC/3TC/ZDV
(Trizivir®) twice daily or ATV (once daily) + 3TC/ZDV (twice daily).
Outcomes 1. HIV-1 viral load
2. CD4+/CD8+ lymphocyte subsets
3. Clinical chemistry
4. Hematology
5. Serum lipid panels
6. Insulin
7. Hemoglobin
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were “randomized 1:1:1” suggest-
ing block randomisation, and presumable
computer-generated
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Blinding: No blinding
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 9% in the ABC/3TC/
ZDV and 10% in the ATV + 3TC/ZDV
groups
Selective reporting (reporting bias) Low risk No
Shapiro 2010
Methods Sequence generation: Computer-generated randomisation sequence
Allocation concealment: Patients were randomised 1:1:1 to Trizivir, Kaletra or Combivir
by block permutation according to clinical site. Randomisation was assigned by calling
the Data Management Centre in Gaborone (Central randomisation)
Blinding: Not described
Loss to follow-up: 15/285 in Trizivir group, 13/275 in kaletra group, and 5/170 in
observational group left the study but reasons not given
Analysis: Not mentioned
Participants 560 pregnant women with HIV-1 infection were recruited between 2006 and 2008 in
Botswana
Inclusion criteria included confirmed HIV-1 infection, age at least 18yrs, 26 to 34 weeks
of gestation, haemoglobin level of at least 8.0g/deciliter, absolute neutrophil count of
at least 1000 cells per cubic millimeter, alanine aminotransferase and aspartate amino-
transferase levels at most 2 times the upper limit of normal and women who preferred
to exclusively feed their babies by formula were excluded
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Interventions Patients meeting inclusion criteria were randomised 1:1 to receive ABC/3TC/ZDV
(Trizivir®) twice daily or co-formulated lopinavir and ritonavir (Kaletra) twice daily +
3TC/ZDV (Combivir) twice daily
Outcomes HIV viral load(viral suppression to <400 and <50 copies/ml)
Mother-to-child transmission intrapartum and postpartum
Adverse events
Notes Study protocol available at: http://www.nejm.org/doi/suppl/10.1056/
NEJMoa0907736/suppl file/nejmoa0907736 protocol.pdf
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk All randomisation assignments were made
based upon computer-generated lists
Allocation concealment (selection bias) Low risk Central randomisation
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Not described
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up: 5.2% in the Trizivir®
and 5.1% in Keletra® arms left the study
for reasons that are not stated.
Selective reporting (reporting bias) Low risk No
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ait-Khaled 2002 Abacavir, lamivudine, zidovudine not used as a fixed-dose combination
Cahn 2004 Abacavir, lamivudine, zidovudine not used as a fixed-dose combination
d’Ettorre 2009 Abstract and article not available and authors did not respond to article request
Feinberg 2003 Abacavir, lamivudine, zidovudine not used as a fixed-dose combination
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Matheron 2003 Abacavir, lamivudine, zidovudine not used as a fixed-dose combination
Munderi 2010 Abacavir, lamivudine, zidovudine not used as a fixed-dose combination
Ndembi 2010 Abacavir, lamivudine, zidovudine not used as a fixed-dose combination
Shao 2009 Co-formulated abacavir-lamivudine-zidovudine not compared to PI or NNRTI regimens
Sprenger 2010 Co-formulated abacavir-lamivudine-zidovudine used as maintenance therapy
Staszewski 2001 Abacavir, lamivudine, zidovudine not used as a fixed-dose combination
Vibhagool 2004 Abacavir, lamivudine, zidovudine not used as a fixed-dose combination
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D A T A A N D A N A L Y S E S
Comparison 1. Fixed-dose NRTI versus PI or NNRTI




participants Statistical method Effect size
1 Virologic failure 3 1687 Risk Ratio (M-H, Random, 95% CI) 1.14 [0.56, 2.31]
2 Virologic suppression
(<400copies/ml)
4 2247 Odds Ratio (M-H, Random, 95% CI) 0.73 [0.39, 1.36]
3 Virologic suppression
(<50copies/ml)
4 2247 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.75, 1.25]
4 CD4 cell count 3 1687 Std. Mean Difference (IV, Random, 95% CI) -0.01 [-0.11, 0.09]
5 Severe adverse events 4 2247 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.78, 1.92]
6 Hypersensitivity 4 2242 Risk Ratio (M-H, Random, 95% CI) 4.04 [0.41, 40.02]
W H A T ’ S N E W
Last assessed as up-to-date: 13 January 2013.
Date Event Description
29 January 2013 New search has been performed Update of review.
29 January 2013 New citation required and conclusions have changed One new trial found (Shapiro 2010) and included. Title
and conclusions changed.
H I S T O R Y
Protocol first published: Issue 4, 2005
Review first published: Issue 3, 2009
Date Event Description
24 June 2008 New citation required and minor changes Substantive amendment
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